GdDO3NI allows imaging of hypoxia after brain injury

Babak Moghadas¹, Vimala N. Bharadwaj¹, John P. Tobey¹, Yanqing Tian²,

Sarah E. Stabenfeldt¹ and, Vikram D. Kodibagkar^{1*}

¹School of Biological and Health Systems Engineering, Arizona State University

²Department of Materials Science and Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China

*Correspondence

Vikram D. Kodibagkar

School of Biological and Health Systems Engineering

Arizona State University, Tempe, AZ 85287-9709.

Email: Vikram.Kodibagkar@asu.edu

Word count : 3020

Running Head: Imaging hypoxia post brain injury

KEYWORDS: HYPOXIA, TBI, MRI, GdDO3NI, TARGETED CONTRAST AGENT

Imaging hypoxia post brain injury

ABSTRACT

Purpose: In this study, we use the hypoxia targeting agent (GdDO3NI, a nitroimidazole-based T₁ MRI contrast agent) for imaging hypoxia in the injured brain after experimental traumatic brain injury (TBI) using magnetic resonance imaging (MRI), and validate the results with immunohistochemistry (IHC) using pimonidazole.

Methods: TBI induced mice (controlled cortical impact model) were imaged at 7T using a T₂ weighted fast spin-echo sequence to estimate the extent of the injury. The mice were then intravenously injected with either conventional T₁ agent (gadoteridol) or GdDO3NI at 0.3 mmol/kg dose (n=5 for each cohort) along with pimonidazole (60 mg/kg). Mice were imaged pre- and post-contrast using a T₁-weighted spin-echo sequence for three hours. Regions of interests were drawn on the brain injury region, the contralateral brain as well as on the cheek muscle region for comparison of contrast kinetics. Brains were harvested immediately post imaging for immunohistochemical analysis.

Results: GdDO3NI is retained in the injury region for up to 3 hours post-injection ($p < 0.05$ compared to gadoteridol) while it rapidly clears out of the muscle region. On the other hand, conventional MRI contrast agent gadoteridol clears out of both the injury region and muscle rapidly, although with a relatively more delayed wash out in the injury region. Minimal contrast enhancement was seen for both agents in the contralateral hemisphere. Pimonidazole staining confirms the presence of hypoxia in both gadoteridol and GdDO3NI cohorts, and the later cohort shows good agreement with MRI contrast enhancement.

Conclusion: GdDO3NI was successfully shown to visualize hypoxia in the brain post-TBI using T₁-wt MRI.

Imaging hypoxia post brain injury

1. Introduction

Traumatic brain injury (TBI) occurs due to damage to the brain resulting from an external mechanical force, including rapid acceleration or deceleration, blast waves, crushing force, an impact, or penetration by a projectile(1). An estimated 1.7 million TBI occur annually in the U.S., which results in the hospitalization of 373,000, and 99,000 totally disabled individuals, and over 50,000 deaths (2,3). Disabilities as well as cognitive, behavioral, and productivity problems are the most common complications for survivors; in acute cases, the affected individuals face mortality(4,5). Upon sustaining a TBI, the mechanical forces from impact inflict heterogeneous tissue damage, referred to as the primary injury phase(1). This insult initiates a myriad of pathophysiological and biochemical secondary injury signaling cascades, including hypo- or hyper-perfusion, edema, blood-brain barrier (BBB) dysfunction, and inflammation that evolves from minutes to days post-trauma(6-8).

Brain tissue hypoxia, defined as brain tissue oxygen tension (pO_2) < 15 mm Hg, is a common consequence of TBI due to the rupture of blood vessels during impact(9). Studies have reported about 30-50% of TBI patients to have hypoxia as early as arriving in an emergency room(10,11). It is shown that brain hypoxia, as one of the post-traumatic insults, is associated with mortality and poor and unfavorable neurological outcomes(12-17). Tissue hypoxia has a significant cross-talk with inflammatory processes, whereby hypoxia can trigger the upregulation of proinflammatory cytokines, and the resulting inflammation can further exacerbate hypoxia due to an increase in the metabolic demands of cells and a reduction in metabolic substrates caused by thrombosis, trauma, compression (interstitial hypertension)(18). Cellular signaling continues acutely and post-

Imaging hypoxia post brain injury

acutely to restore homeostasis in injured tissue, which, if not controlled, can exacerbate the injury(8,19). Furthermore, studies suggest brain tissue oxygen-based therapy can reduce mortality rate and ameliorate neurological outcome for the patients (20,21).

Noninvasive characterization of the injury microenvironment is often difficult to achieve through conventional neuroimaging methods (e.g. Computed tomography (CT), T1w and T2w Magnetic Resonance Imaging (MRI)) as they are not sensitive enough to identify regions undergoing microstructural changes (22-24). The CT scan is highly effective in detecting TBI induced skull fractures, bleeding within and surrounding the brain (hematomas) as well as brain swelling (edema) and the resolution of these over time. CT is much more limited in its ability to detect the widespread microscopic injury to axons which leads to many of the long-term problems experienced by TBI patients. MRI is a powerful diagnostic tool that can detect signs of injury such as minute bleeding (microhemorrhage), small areas of bruising (contusion) or scarring (gliosis), which are invisible to the CT scan. Several MR-based neuroimaging modalities have been used to qualitatively examine acute and chronic changes post TBI longitudinally (25,26): (a) fluid-attenuated inversion recovery (FLAIR) MRI, a sequence that suppresses the high signal from CSF, is sensitive in detecting traumatic lesions and hematomas, (b) T₁-weighted structural MRI is sensitive to morphological changes in gray matter volume and cortical thickness, (c) diffusion-weighted MRI (DWI) is sensitive to changes in the microstructural integrity of white matter, (d) MR spectroscopy provides a sensitive assessment of metabolic and neurochemical alterations in the brain, and (e) T₂*-weighted blood oxygen level dependent (BOLD) functional MRI (fMRI) provides insight into the functional changes that occur as a result of structural damage and typical developmental

Imaging hypoxia post brain injury

processes. BOLD fMRI only reflects vascular oxygenation and it cannot provide data in regions where BBB is disrupted. An unmet need in TBI diagnosis is the ability to assess tissue oxygenation or hypoxia.

Among various invasive techniques to detect hypoxia, the 2-nitroimidazole pimonidazole, has been previously demonstrated to be reliable in detecting hypoxic regions in tissue (27). After intravenous administration and extravasation, pimonidazole gets activated under hypoxia and binds to thiol-containing proteins in hypoxic regions, and these adducts can be detected *ex vivo* utilizing immunohistochemistry (IHC) in conjunction with fluorescent microscopy (28). In addition, several noninvasive imaging approaches to assess hypoxia (qualitatively or quantitatively) have been developed and are in various stages of validation from preclinical to clinical use (29). Currently, [^{18}F]Fluoromisonidazole (^{18}F -MISO) [^{18}F]fluoroazomycin arabinoside (FAZA) (30), [^{18}F]-EF5 (31), [^{18}F] fluoroerythronitroimidazole (FETNIM) (32) and Cu-labelled diacetyl-bis(*N*(4)-methylthiosemicarbazone (Cu-ATSM) are being used as hypoxia targeting PET imaging agents (33). While PET based probes have significantly advanced the field of hypoxia imaging, there is a strong rationale for the development of MRI based hypoxia-imaging techniques as well due to the ability of MRI to acquire higher resolution anatomical and complementary functional information in the same scanning session. BOLD and tissue oxygen level-dependent (TOLD) signal (34-37) and [^{19}F] Tri-fluoromisonidazole (TF-MISO)(38,39) are MRI techniques to qualitatively image hypoxia while ^{19}F (29,40) and ^1H (41-43) based MR oximetry techniques quantitatively measure pO_2 in tumors and muscle tissue. Recently, a novel nitroimidazole-based T1 contrast agent, gadolinium tetraazacyclododecanetetraacetic acid monoamide conjugate of 2-

Imaging hypoxia post brain injury

nitroimidazole (GdDO3NI, MW = 839 g/mol), was used to measure hypoxia, non-invasively by MRI, *in vitro* using 9L glioma cells (44) and *in vivo* in a rat prostate cancer model (45) and MRI contrast enhancement showed correlation with pimonidazole staining. The relaxivity values of GdDO3NI were reported as $r_1=4.75\pm0.04 \text{ s}^{-1}\text{mM}^{-1}$ and $r_2=7.52\pm0.07 \text{ s}^{-1}\text{mM}^{-1}$ at 37 °C and 7 T(46).

The objective of the present study is to utilize GdDO3NI enhanced MRI, for high resolution visualization of hypoxia in the rodent brain post TBI and to validate MRI data with pimonidazole based IHC. Here, we used the controlled cortical impact (CCI) injury model (47) to recapitulate elements of a focal TBI including focal lesion, axonal injury, BBB disruption, and necrosis (48,49).

2. Materials and Methods

2.1. Materials

ProHance (Gadoteridol; Bracco Diagnostics Inc., Monroe Township, NJ, USA), was used as control contrast agent. GdDO3NI, was synthesized as described previously(44). Briefly, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) was selected as Gd chelator along with conjugation to 2-nitroimidazole for hypoxia targeting. Pimonidazole and FITC linked mouse anti-pimonidazole MAb (Hypoxypore Inc, Burlington, MA, USA) was used as the gold standard hypoxia indicator in tissue through IHC staining.

2.2. Animal preparation

All animal studies were approved by Arizona State University's Institute of Animal Care and Use Committee (IACUC) and were performed in accordance with the relevant guidelines. Two cohorts of 5 animals each were used in this study. All the procedures on

Imaging hypoxia post brain injury

animals were performed under isoflurane (Baxter International Inc, Deerfield, IL). TBI was simulated using the CCI model of TBI (47). Briefly, adult male C57Bl/6 mice (9-11 weeks old) placed in stereotaxic frame under isoflurane anesthesia (3% induction, 1.5% maintenance). The frontoparietal cortex was exposed via 3 mm craniotomy and the impact tip was centered at -1.5 mm bregma and 1.5 mm lateral from midline. The impactor tip diameter was 2 mm, the impact velocity was 6.0 m/s and the depth of cortical deformation was 2 mm with 100 ms impact duration (Impact ONE; Leica Microsystems). After the impact, the skin was sutured, and the animal was catheterized for tail vein injection. Once the catheter was connected, the animal was placed onto temperature controllable MR bed and kept at 37 °C and under anesthesia (isoflurane at 1.5%).

2.3. Magnetic resonance imaging

MRI studies were carried out on a 7 T Bruker system with a surface coil. Mice were placed into the magnet right after the injury and pre-injection T_2 and T_1 weighted scans were acquired in a one hour window after injury and before injection of contrast agents. A cocktail of 60 mg/kg pimonidazole (hypoxia marker) and 0.3 mmol/kg of either MRI agents (gadoteridol or GdDO3NI) in a 100 μ L volume was injected via intravenous injection at 1 hour post-injury and follow-up imaging began right after the injection. Multi gradient echo (MGE) sequence with TR= 80 ms, TE= 3 ms, flip angle= 35°, image acquisition time=5min 27s, and FOV (2 cm X 2 cm X 2 cm) were used to monitor the contrast agent uptake in the site of injury over a period of three hours with 10 min intervals after injury. Image data (k-space) were acquired with grid size of 128*64*64 and zero-filled to 128*128*128 for further analysis.

Imaging hypoxia post brain injury

2.4. Data processing

Acquired data was processed using custom-written scripts in MATLAB. Regions of interests (ROI) for the muscle, injury, and the contralateral brain were manually delineating on the T₂ maps, for each animal. These were registered and applied to the time course T₁-wt images as masks to extract data for further analysis. From these data, the injury volume, normalized differential enhancement (NDE) and the contrast agent retention fraction, were calculated for each animal NDE is defined as the difference in percentage enhancement between the injury region and the contralateral brain and divided by the maximum value of the muscle enhancement for each data set. NDE is used to reduce the influence of normal muscle and brain contrast retention, ensuring the calculated enhancement is due to injury-induced hypoxia. The contrast agent retention fraction is calculated as the fraction of pixels in the injury region with NDE values greater than the mean NDE + standard deviation of the conventional contrast agent cohort. The contrast agent retention fraction is used to discern the additional contrast retention of GdDO3NI when compared to gadoteridol. The pre-injection and 3-hour post-injection scans were used to create 3D percentage contrast enhancement maps for each animal using the 3D Slicer software (<http://www.slicer.org>). A percentage enhancement range between 10% and 100% were used to display the 3D videos of hypoxic regions (Supplementary data) to show the spatial extent and degree of contrast retention.

2.5. Statistics

All results are reported as means $\pm$ standard deviations (SD). Statistical comparisons were made between time-course gadoteridol and GdDO3NI data using analysis of

Imaging hypoxia post brain injury

variance (ANOVA). In pairwise statistical evaluations, the Tukey ($\alpha = 0.05$, 95% confidence intervals) test was used between specific means.

2.6. Tissue Collection

The excision and fixing of the brain tissue was performed as reported previously (50). Immediately after imaging, animals were deeply anesthetized with lethal dose of sodium pentobarbital solution. Once a tail pinch produced no reflex movement, animals were transcardially perfused with cold phosphate-buffered saline (PBS), followed by 4 % (w/v) buffered paraformaldehyde solution. Whole brain tissue was harvested and fixed overnight in 4 % (w/v) buffered paraformaldehyde solution. The following day, brains were immersed in 30 % (w/v) sucrose solution in 1X PBS for cryoprotection until the tissue was fully infiltrated. Samples were embedded in optimal cutting temperature medium and frozen on dry ice. Samples were stored at -80°C until sectioned coronally at a $20\text{ }\mu\text{m}$ thickness with a cryostat (CryoStar™ NX70; Thermo Fisher Scientific) and collected onto positively charged microscope slides. Slides were retained in -80°C refrigerator for further staining and analyses.

2.7. Histology and immunohistochemistry

Pimonidazole staining was performed using FITC-conjugated anti-pimonidazole antibody. The slides, which were kept in -80°C were moved to the -20°C freezer for 20-30 minutes. Then, they were moved to a 4°C refrigerator for 15-20 minutes before being moved to room temperature PBS in a glass slide staining rack to avoid the temperature shock. The slides were moved to a tray and covered with the blocking buffer for 1 h. The slides were then washed using the waterfall technique with 1X PBS three times and were placed in the glass station filled with 1x PBS for 5 minutes and washed again. Following that, slides

Imaging hypoxia post brain injury

were placed in a tray and moved to 4 °C refrigerator and covered with 100 µL of the FITC conjugated anti pimonidazole antibody and incubation buffer mixture for overnight incubation.

Sections were then washed with 1 mL of 1X PBS for three times in a dimmed light room and incubated with the nuclear stain DAPI (4',6-diamidino-2-phenylindole) to help in identification of tissue in final visualization. Microscope images were acquired using a Leica microscope with 355-425 nm excitation / LP 470 nm emission filter for DAPI and 450-490 nm excitation / 500-550 nm emission filter for FITC.

3. Results

To verify the consistency of the TBI modeling, we calculated the injury volume for each cohort using MR images. T2 wt MRI allowed for delineation of injury regions and quantification of injury volumes in the gadoteridol and GdDO3NI injected cohorts at 1 hr post-injury. The mean injury volumes for the gadoteridol and GdDO3NI cohorts were $4.82 \pm 0.50 \text{ mm}^3$ and $5.23 \pm 1.13 \text{ mm}^3$, respectively ($p > 0.05$). Fig. 1 shows the dynamic percentage enhancement maps of a representative animal from the gadoteridol (top row) and GdDO3NI injected animal over the course of three hours post-injection. The region of interest (ROI) defining the injury region is indicated using a white arrow on T₂ weighted and T₁ weighted images. The color map overlay represents the percentage changes in pixel intensities with respect to the pre-injection value. Gadoteridol (Fig 1, top row) shows almost complete clearance from the injury region while GdDO3NI (bottom row) shows significant accumulation at 3 hr post injection. Fig. 2a shows the mean time-course NDE of the two cohorts over three hours post-injection. Statistical analysis showed significant differences ($p < 0.05$) in NDE of the injury region after 150 min between gadoteridol and

Imaging hypoxia post brain injury

GdDO3NI cohorts. The distribution of pooled NDE values over all animals (Fig. 2b) further underline the differences between the two agents. The ROI analysis for both contrast agents revealed changes in the signal intensity in injury site and muscle but almost no changes in the healthy contralateral region over the three hours (Supplementary figure 1). The intensity enhancement values in muscle showed rapid changes compared to the injury region that was slow and prolonged. Comparing the two cohorts (n=5) shows statistically significant retention ($p < 0.05$) of GdDO3NI in the injured region with significantly lower retention of gadoteridol at 150 minutes post-injection or later with the contrast agent retention factor values of 63.95 ± 27.43 % and 20.68 ± 7.43 %, respectively, at 3 hr post injection (4 hr post injury). In order to visualize the hypoxic regions in 3D, the maps of hypoxia and videos were generated. Fig. 3 (a, b) illustrate the 3D visualization of percentage enhancement at 3 hr post-injection for a representative animal from each cohort which shows the difference between the enhancement of each contrast agent can be seen, and the volumetric extent of the contrast agent retention. Corresponding videos (Supplementary data) allow for complete visualization of the injury region within the brain. Table 1 summarizes the injury volumes, NDE and the contrast agent retention factor for each animal as well as the means and standard deviations. We performed pimonidazole-based immunohistochemical staining of the brain sections for each cohort to study the presence of hypoxia and sections from corresponding representative animals in Fig. 2 and Fig. 3 are shown in Fig. 4. The DAPI staining is presented in blue and pimonidazole staining in green. The results from both cohorts confirmed the presence of pimonidazole in the injury region.

Imaging hypoxia post brain injury

4. Discussion and Conclusions

The mean volume of injury for gadoteridol injected cohort and the GdDO3NI injected cohort showed no statistically significant difference between the cohorts, indicating the consistency of the lesion volume and TBI modeling across the animals. Our results showed the contrast agent retention factor was significantly different in the two cohorts. Under normal physiological conditions, small molecular non-targeting Gd contrast agents such as gadoteridol, once introduced to the bloodstream, do not extravasate into brain tissue due to the tightly regulated BBB (unlike the muscle tissue). In pathologies that disrupt the BBB (e.g TBI or brain tumors), dynamic contrast enhanced MRI shows accumulation and clearance of the contrast agent from the affected region enabling the estimation of BBB leakiness (51,52). GdDO3NI and gadoteridol had similar, slower uptake pharmacokinetics in the brain injury region compared to muscle in each case. This observation can be attributed to the complex dynamic of the injured brain and blood flow disruption due to BBB dysfunction in the injury region compared to the intact muscle (53). In contrast, the clearance pharmacokinetics of the two agents (GdDO3NI and gadoteridol) were markedly distinct in the injured brain while they were similar in the muscle region. In absence of hypoxia in the muscle, GdDO3NI behaves like any other small molecular MRI contrast agent, including gadoteridol) with uptake/clearance kinetics that are predominantly flow-limited (54). However, in the hypoxic injured region, the two agents behave differently, with GdDO3NI binding to proteins, via the 2-nitroimidazole moiety of the agent, showing significantly longer retention times compared to gadoteridol. This mechanism has been previously shown in prostate tumors as well where GdDO3NI was retained in hypoxic regions compared to a non-targeting Gd agent (45) . A qualitative

Imaging hypoxia post brain injury

comparison between the MRI and IHC images shows a good agreement between the location of T1 hyper-intensity regions within in the injury site in the GdDO3NI cohort and pimonidazole binding. These observations confirm our hypothesis that GdDO3NI localizes in hypoxic regions in TBI.

The contrast agent retention factor reflects the amount of contrast agent in the injury region at the 3 hr post injection. While we see significant differences in the retention of gadoteridol compared to GdDO3NI, the former does not appear to be completely eliminated possibly due to the irreversible retention (51). The dynamic nature of the BBB dysfunction can influence the amount of exogenous agents that are able to wash in or wash out, even over a matter of hours post injury, due to dynamic reduction in BBB leakiness (55). Our results showed the GdDO3NI cohort had significantly higher retention values compared to gadoteridol that can only be attributed to binding in the hypoxic regions. In case of the GdDO3NI the retention fraction is related to the hypoxic fraction but, unlike tumors, it may overestimate the hypoxic fraction due to some degree of irreversible retention arising from acute reduction in BBB leakiness over 3 hrs since the contrast agent was injected (as seen for the control agent, gadoteridol). The IHC results from both cohorts confirmed the presence of hypoxia post TBI; however, only animals in the GdDO3NI cohort were able to represent that in MRI contrast enhancement studies.

In summary, the results demonstrate that contrast enhanced MRI using GdDO3NI allows visualization of hypoxic regions in the brain following TBI. The MR results were validated by the gold standard method of IHC staining for pimonidazole. Non-invasive imaging of hypoxia in TBI could allow for injury prognosis as well as personalized treatment targeted towards alleviation of hypoxia.

Imaging hypoxia post brain injury

ACKNOWLEDGMENTS

This study was supported in part by a National Science Foundation CAREER Award#1351992 (V. D. K), a “Rising Stars in Engineering” seed grant from the Fulton Schools of Engineering, ASU (V.D.K., S.E.S.), a FLINN Foundation grant (S.E.S., V.D.K.), NIH 1DP2HD084067 (S.E.S.) and Arizona State University Graduate College Completion Fellowship (B.M. and V.N.B.). Imaging studies were performed at the Barrow-ASU Center for Preclinical Imaging, a part of the Biosciences Core Facilities at Arizona State University.

Imaging hypoxia post brain injury

References:

1. McIntosh TK, Saatman KE, Raghupathi R, Graham DI, Smith DH, Lee VM, Trojanowski JQ. The Dorothy Russell Memorial Lecture. The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms. *Neuropathology and applied neurobiology* 1998;24(4):251-267.
2. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. *The Journal of head trauma rehabilitation* 2006;21(5):375-378.
3. Chi JH, Knudson MM, Vassar MJ, McCarthy MC, Shapiro MB, Mallet S, Holcroft JJ, Moncrief H, Noble J, Wisner D, Kaups KL, Bennick LD, Manley GT. Prehospital hypoxia affects outcome in patients with traumatic brain injury: a prospective multicenter study. *The Journal of trauma* 2006;61(5):1134-1141.
4. Flanagan SR. Invited Commentary on "Centers for Disease Control and Prevention Report to Congress: Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation". *Archives of physical medicine and rehabilitation* 2015;96(10):1753-1755.
5. Bryant RA, O'Donnell ML, Creamer M, McFarlane AC, Clark CR, Silove D. The psychiatric sequelae of traumatic injury. *The American journal of psychiatry* 2010;167(3):312-320.
6. Emery DL, Royo NC, Fischer I, Saatman KE, McIntosh TK. Plasticity following Injury to the Adult Central Nervous System: Is Recapitulation of a Developmental State Worth Promoting? *Journal of Neurotrauma* 2003;20(12):1271-1292.
7. Masel BE, DeWitt DS. Traumatic Brain Injury: A Disease Process, Not an Event. *Journal of Neurotrauma* 2010;27(8):1529-1540.
8. Simon DW, McGeachy MJ, Bayir H, Clark RSB, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. *Nature Reviews Neurology* 2017;13(3):171-191.
9. Alejandro M. Spiotta, Michael F. Stiefel, Vicente H. Gracias, Alicia M. Garuffe, W. Andrew Kofke, Eileen Maloney-Wilensky, Andrea B. Troxel, Joshua M. Levine, Peter D. Le Roux. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. *Journal of Neurosurgery* 2010;113(3):571-580.
10. Ishige N, Pitts LH, Berry I, Carlson SG, Nishimura MC, Moseley ME, Weinstein PR. The Effect of Hypoxia on Traumatic Head Injury in Rats: Alterations in Neurologic Function, Brain Edema, and Cerebral Blood Flow. *Journal of Cerebral Blood Flow & Metabolism* 1987;7(6):759-767.
11. Sinha RP, Ducker TB, Perot PL, Jr. Arterial oxygenation: Findings and its significance in central nervous system trauma patients. *JAMA* 1973;224(9):1258-1260.
12. Oddo M, Levine JM, Mackenzie L, Frangos S, Feihl F, Kasner SE, Katsnelson M, Pukenas B, Macmurtrie E, Maloney-Wilensky E, Kofke WA, LeRoux PD. Brain Hypoxia Is Associated With Short-term Outcome After Severe Traumatic Brain Injury Independently of Intracranial Hypertension and Low Cerebral Perfusion Pressure. *Neurosurgery* 2011;69(5):1037-1045.
13. Bardt TF, Unterberg AW, Härtl R, Kiening KL, Schneider GH, Lanksch WR. Monitoring of Brain Tissue PO₂ in Traumatic Brain Injury: Effect of Cerebral Hypoxia on Outcome. *Intracranial Pressure and Neuromonitoring in Brain Injury*; 1998; Vienna. Springer Vienna. p 153-156. (*Intracranial Pressure and Neuromonitoring in Brain Injury*).
14. Chesnut RM, Marshall SB, Piek J, Blunt BA, Klauber MR, Marshall LF. Early and Late Systemic Hypotension as a Frequent and Fundamental Source of Cerebral Ischemia Following Severe Brain Injury in the Traumatic Coma Data Bank. In: Unterberg AW, Schneider G-H, Lanksch WR, editors. *Monitoring of Cerebral Blood Flow and Metabolism in Intensive Care*. Vienna: Springer Vienna; 1993. p 121-125.

Imaging hypoxia post brain injury

15. Jeremitsky E, Omert L, Dunham CM, Protetch J, Rodriguez A. Harbingers of Poor Outcome the Day after Severe Brain Injury: Hypothermia, Hypoxia, and Hypoperfusion. *Journal of Trauma and Acute Care Surgery* 2003;54(2):312-319.
16. Mrozek S, Luzzi A, Gonzalez L, Kerhuel L, Fourcade O, Geeraerts T. Cerebral and extracerebral vulnerability to hypoxic insults after diffuse traumatic brain injury in rats. *Brain Research* 2016;1646:334-341.
17. Yan Edwin B. SL, Paul Eldho, Bye Nicole, Nguyen Phuong, Agyapomaa Doreen, Kossmann Thomas, Rosenfeld Jeffrey V., and Morganti-Kossmann Maria Cristina. . Post-Traumatic Hypoxia Is Associated with Prolonged Cerebral Cytokine Production, Higher Serum Biomarker Levels, and Poor Outcome in Patients with Severe Traumatic Brain Injury *Journal of Neurotrauma* March 2014(31(7)):618-629.
18. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. *The New England journal of medicine* 2011;364(7):656-665.
19. Prakash R, Carmichael ST. Blood–brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury:. *Current Opinion in Neurology* 2015;28(6):556-564.
20. Spiotta AM, Stiefel MF, Gracias VH, Garuffe AM, Kofke WA, Maloney-Wilensky E, Troxel AB, Levine JM, Le Roux PD. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. *J Neurosurg* 2010;113(3):571-580.
21. Stiefel MF, Spiotta A, Gracias VH, Garuffe AM, Guillaumondegui O, Maloney-Wilensky E, Bloom S, Grady MS, LeRoux PD. Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring. *J Neurosurg* 2005;103(5):805-811.
22. Aribisala BS, Cowie CJA, He J, Wood J, Mendelow AD, Mitchell P, Blamire AM. Multi-parametric classification of traumatic brain injury patients using automatic analysis of quantitative MRI scans. *Proceedings of the 5th international conference on Medical imaging and augmented reality: Springer-Verlag; 2010. p 51-59.*
23. Galloway NR, Tong KA, Ashwal S, Oyoyo U, Obenaus A. Diffusion-weighted imaging improves outcome prediction in pediatric traumatic brain injury. *J Neurotrauma*. 2008/10/10 ed. Volume 25; 2008. p 1153-1162.
24. Mayer AR, Ling J, Mannell MV, Gasparovic C, Phillips JP, Doezeema D, Reichard R, Yeo RA. A prospective diffusion tensor imaging study in mild traumatic brain injury. *Neurology*. 2010/01/22 ed. Volume 74; 2010. p 643-650.
25. Lee B, Newberg A. Neuroimaging in traumatic brain imaging. *NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics* 2005;2(2):372-383.
26. Lindsey HM, Wilde EA, Caeyenberghs K, Dennis EL. Longitudinal Neuroimaging in Pediatric Traumatic Brain Injury: Current State and Consideration of Factors That Influence Recovery. *Frontiers in neurology* 2019;10:1296.
27. Raleigh JA, Dewhirst MW, Thrall DE. Measuring Tumor Hypoxia. *Seminars in radiation oncology* 1996;6(1):37-45.
28. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC, Jr., Raleigh JA. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. *Gynecologic oncology* 1998;71(2):270-277.
29. Zhao D, Jiang L, Mason RP. Measuring changes in tumor oxygenation. *Methods in enzymology* 2004;386:378-418.
30. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. *J Nucl Med* 2005;46(1):106-113.

Imaging hypoxia post brain injury

31. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR, Jr., Koch CJ. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. *J Nucl Med* 2000;41(2):327-336.
32. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. *Radiology* 1995;194(3):795-800.
33. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. *J Nucl Med* 2008;49 Suppl 2:129S-148S.
34. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO₂) inside tumors? *Magn Reson Med* 2002;48(6):980-986.
35. Zhou H, Chiguru S, Hallac RR, Yang D, Hao G, Peschke P, Mason RP. Examining correlations of oxygen sensitive MRI (BOLD/TOLD) with [(18)F]FMISO PET in rat prostate tumors. *American journal of nuclear medicine and molecular imaging* 2019;9(2):156-167.
36. Hallac RR, Zhou H, Pidikiti R, Song K, Stojadinovic S, Zhao D, Solberg T, Peschke P, Mason RP. Correlations of noninvasive BOLD and TOLD MRI with pO₂ and relevance to tumor radiation response. *Magn Reson Med* 2014;71(5):1863-1873.
37. Ding Y, Mason RP, McColl RW, Yuan Q, Hallac RR, Sims RD, Weatherall PT. Simultaneous measurement of tissue oxygen level-dependent (TOLD) and blood oxygenation level-dependent (BOLD) effects in abdominal tissue oxygenation level studies. *Journal of magnetic resonance imaging : JMIR* 2013;38(5):1230-1236.
38. Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB, Matei C, Ling CC, Koutcher JA. In vivo ¹⁹F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. *Clin Cancer Res* 2007;13(12):3738-3747.
39. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. *Radiother Oncol* 1991;20 Suppl 1:13-19.
40. Mason RP, Rodbumrung W, Antich PP. Hexafluorobenzene: a sensitive ¹⁹F NMR indicator of tumor oxygenation. *NMR in Biomedicine* 1996;9(3):125-134.
41. Gulaka PK, Rastogi U, McKay MA, Wang X, Mason RP, Kodibagkar VD. Hexamethyldisiloxane-based nanoprobe for (1) H MRI oximetry. *NMR Biomed* 2011;24(10):1226-1234.
42. Kodibagkar VD, Cui WN, Merritt ME, Mason RP. Novel H-1 NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. *Magnetic Resonance in Medicine* 2006;55(4):743-748.
43. Kodibagkar VD, Wang X, Pacheco-Torres J, Gulaka P, Mason RP. Proton imaging of siloxanes to map tissue oxygenation levels (PISTOL): a tool for quantitative tissue oximetry. *NMR Biomed* 2008;21(8):899-907.
44. Rojas-Quijano FA, Tircso G, Tircsone Benyo E, Baranyai Z, Tran Hoang H, Kalman FK, Gulaka PK, Kodibagkar VD, Aime S, Kovacs Z, Sherry AD. Synthesis and characterization of a hypoxia-sensitive MRI probe. *Chemistry* 2012;18(31):9669-9676.
45. Gulaka PK, Rojas-Quijano F, Kovacs Z, Mason RP, Sherry AD, Kodibagkar VD. GdDO₃NI, a nitroimidazole-based T₁ MRI contrast agent for imaging tumor hypoxia in vivo. *Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry* 2014;19(2):271-279.
46. Agarwal S. MRI Guided Analysis of Changes in Tumor Oxygenation in Response to Hypoxia Activated/Targeted Therapeutics [Doctoral Dissertation]: Arizona State University; 2017. 181 p.
47. Smith DH, Soares HD, Pierce JS, Perlman KG, Saatman KE, Meaney DF, Dixon CE, McIntosh TK. A Model of Parasagittal Controlled Cortical Impact in the Mouse - Cognitive and Histopathologic Effects. *Journal of Neurotrauma* 1995;12(2):169-178.

Imaging hypoxia post brain injury

48. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. *Journal of neuroscience methods* 1991;39(3):253-262.
49. Osier ND, Dixon CE. The Controlled Cortical Impact Model: Applications, Considerations for Researchers, and Future Directions. *Frontiers in neurology* 2016;7.
50. Jonkers BW, Sterk JC, Wouterlood FG. Transcardial perfusion fixation of the CNS by means of a compressed-air-driven device. *Journal of neuroscience methods* 1984;12(2):141-149.
51. Li W, Long JA, Watts LT, Jiang Z, Shen Q, Li Y, Duong TQ. A quantitative MRI method for imaging blood-brain barrier leakage in experimental traumatic brain injury. *PloS one* 2014;9(12):e114173.
52. Kording F, Weidensteiner C, Zwick S, Osterberg N, Weyerbrock A, Staszewski O, von Elverfeldt D, Reichardt W. Simultaneous assessment of vessel size index, relative blood volume, and vessel permeability in a mouse brain tumor model using a combined spin echo gradient echo echo-planar imaging sequence and viable tumor analysis. *Journal of magnetic resonance imaging : JMRI* 2014;40(6):1310-1318.
53. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. *Nature reviews Neurology* 2010;6(7):393-403.
54. Kallehauge JF, Tanderup K, Duan C, Haack S, Pedersen EM, Lindegaard JC, Fokdal LU, Mohamed SMI, Nielsen T. Tracer kinetic model selection for dynamic contrast-enhanced magnetic resonance imaging of locally advanced cervical cancer. *Acta oncologica* 2014;53(8):1064-1072.
55. Bharadwaj VN, Lifshitz J, Adelson PD, Kodibagkar VD, Stabenfeldt SE. Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. *Scientific reports* 2016;6(1):29988.

Imaging hypoxia post brain injury

Figures

Fig 1. MRI T2 weighted scout images and signal enhancement (%) overlay on T1 weighted images of mice brains pre- and post-injection of conventional Gd agent gadoteridol (top row), and GdDO3NI (bottom row) over 3 hrs after injection. White arrow shows location of injury.

Fig 2. Time course mean normalized differential enhancement (NDE) results for gadoteridol and GdDO3NI injected cohort during 3 hrs after injection. NDE is calculated as the difference between the % enhancements of the injury region and a contralateral brain region of interest (ROI) normalized to the peak % enhancement for a muscle ROI.

Fig 3. 3D rendering of hypoxic regions in brains of representative (a) gadoteridol and (b) GdDO3NI injected animal. Color scale represents percentage enhancement at 3 hrs post injection of respective contrast agent. 3D rendering shows both the spatial extent as well as the severity of hypoxia in the GdDO3NI cohort and the degree of residual agent retention in the gadoteridol cohort. Color scale= 10% -100%, scale bar = 5 mm.

Fig 4. Immunohistochemical staining for hypoxia in injured animals (corresponding to fig 1), DAPI is visualized in blue and pimonidazole staining is visualized in green in representative animals injected with (a) gadoteridol or (b) GdDO3NI. Both cohorts display presence of hypoxia post injury. Scale bar = 1 mm.

Imaging hypoxia post brain injury

Fig. 1

Imaging hypoxia post brain injury

Fig. 2a

Fig. 2b

Imaging hypoxia post brain injury

Fig. 3

Imaging hypoxia post brain injury

Fig. 4

Imaging hypoxia post brain injury

Table 1. Injury volume, normalized differential enhancement and contrast agent retention fraction for each animal in the gadoteridol (control) and GdDO3NI cohorts.

Animal number	Injury volume (mm ³)	Normalized Differential Enhancement (NDE)	Contrast agent retention fraction (%)
Gadoteridol			
# 1	4.68	-0.26	15.17
# 2	5.27	-0.04	13.41
# 3	4.58	0.16	32.37
# 4	4.20	0.10	21.71
# 5	5.40	-0.09	20.74
Mean	4.82±0.50	-0.03±0.17	20.68±7.43
GdDO3NI			
# 1	6.81	0.89	51.25
# 2	5.66	0.41	45.32
# 3	3.77	0.18	93.67
# 4	4.69	0.18	36.32
# 5	5.22	0.13	93.20
Mean	5.23±1.13	0.36±0.32*	63.95±27.43*